Lacutamab

DB15322InvestigationalProtein Based Therapies

Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).

Mechanism: Pharmacologically active on Killer cell immunoglobulin-like receptor 3DL2
Curator reviewed
Code names: IPH4102

Resolves to

Compound

UNIIN8O7MY0VNSCAS2187368-16-5

Targets

P43630KIR3DL2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lacutamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account